These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 36257537)

  • 1. Advanced and recurrent endometrial cancer: State of the art and future perspectives.
    Tronconi F; Nero C; Giudice E; Salutari V; Musacchio L; Ricci C; Carbone MV; Ghizzoni V; Perri MT; Camarda F; Gentile M; Berardi R; Scambia G; Lorusso D
    Crit Rev Oncol Hematol; 2022 Dec; 180():103851. PubMed ID: 36257537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker-driven therapy in endometrial cancer.
    Karpel H; Slomovitz B; Coleman RL; Pothuri B
    Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
    Kasherman L; Ahrari S; Lheureux S
    Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
    Green AK; Feinberg J; Makker V
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Ackroyd SA; Huang ES; Kurnit KC; Lee NK
    Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
    Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
    Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing treatments paradigms and role of immunotherapy in recurrent endometrial cancer.
    Chelariu-Raicu A; Mahdi H; Slomovitz BM
    Curr Opin Obstet Gynecol; 2022 Feb; 34(1):28-35. PubMed ID: 34967812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Dilley SE; Smith HJ; Straughn JM
    Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma.
    Walker CA; Spirtos AN; Miller DS
    Expert Rev Anticancer Ther; 2023 Apr; 23(4):361-368. PubMed ID: 36944439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
    Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):717-729. PubMed ID: 38863432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
    Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
    Front Oncol; 2022; 12():844801. PubMed ID: 35494078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
    Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
    Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in endometrial cancer.
    Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; García de Santiago B; Casado Sáenz E
    Crit Rev Oncol Hematol; 2021 May; 161():103306. PubMed ID: 33839243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
    Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
    BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].
    Galienne M; Rodrigues M
    Bull Cancer; 2021; 108(7-8):675-676. PubMed ID: 33994164
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment options for molecular subtypes of endometrial cancer in 2023.
    Karpel HC; Slomovitz B; Coleman RL; Pothuri B
    Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial cancer: Molecular markers and management of advanced stage disease.
    Arend RC; Jones BA; Martinez A; Goodfellow P
    Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
    Sobecki-Rausch J; Barroilhet L
    Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.